Burjanivova Tatiana, Madzo Jozef, Muzikova Katerina, Meyer Claus, Schneider Bjoern, Votava Felix, Marschalek Rolf, Stary Jan, Trka Jan, Zuna Jan
CLIP-Childhood Leukaemia Investigation Prague, Czech Republic.
BMC Cancer. 2006 Apr 21;6:100. doi: 10.1186/1471-2407-6-100.
While there is enough convincing evidence in childhood acute lymphoblastic leukemia (ALL), the data on the pre-natal origin in childhood acute myeloid leukemia (AML) are less comprehensive. Our study aimed to screen Guthrie cards (neonatal blood spots) of non-infant childhood AML and ALL patients for the presence of their respective leukemic markers.
We analysed Guthrie cards of 12 ALL patients aged 2-6 years using immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements (n = 15) and/or intronic breakpoints of TEL/AML1 fusion gene (n = 3). In AML patients (n = 13, age 1-14 years) PML/RARalpha (n = 4), CBFbeta/MYH11 (n = 3), AML1/ETO (n = 2), MLL/AF6 (n = 1), MLL/AF9 (n = 1) and MLL/AF10 (n = 1) fusion genes and/or internal tandem duplication of FLT3 gene (FLT3/ITD) (n = 2) were used as clonotypic markers. Assay sensitivity determined using serial dilutions of patient DNA into the DNA of a healthy donor allowed us to detect the pre-leukemic clone in Guthrie card providing 1-3 positive cells were present in the neonatal blood spot.
In 3 patients with ALL (25%) we reproducibly detected their leukemic markers (Ig/TCR n = 2; TEL/AML1 n = 1) in the Guthrie card. We did not find patient-specific molecular markers in any patient with AML.
In the largest cohort examined so far we used identical approach for the backtracking of non-infant childhood ALL and AML. Our data suggest that either the prenatal origin of AML is less frequent or the load of pre-leukemic cells is significantly lower at birth in AML compared to ALL cases.
虽然儿童急性淋巴细胞白血病(ALL)有足够令人信服的证据,但儿童急性髓系白血病(AML)产前起源的数据却不那么全面。我们的研究旨在筛查非婴儿期儿童AML和ALL患者的格思里卡片(新生儿血斑),以确定是否存在各自的白血病标志物。
我们使用免疫球蛋白(Ig)和T细胞受体(TCR)基因重排(n = 15)和/或TEL/AML1融合基因的内含子断点(n = 3)分析了12例2 - 6岁ALL患者的格思里卡片。在AML患者(n = 13,年龄1 - 14岁)中,PML/RARalpha(n = 4)、CBFbeta/MYH11(n = 3)、AML1/ETO(n = 2)、MLL/AF6(n = 1)、MLL/AF9(n = 1)和MLL/AF10(n = 1)融合基因和/或FLT3基因的内部串联重复(FLT3/ITD)(n = 2)被用作克隆型标志物。通过将患者DNA与健康供体DNA进行系列稀释来确定检测灵敏度,这使我们能够在格思里卡片中检测到白血病前期克隆,前提是新生儿血斑中存在1 - 3个阳性细胞。
在3例ALL患者(25%)中,我们在格思里卡片中可重复地检测到他们的白血病标志物(Ig/TCR n = 2;TEL/AML1 n = 1)。在任何AML患者中我们都未发现患者特异性分子标志物。
在迄今为止检测的最大队列中,我们采用相同方法追溯非婴儿期儿童ALL和AML。我们的数据表明,要么AML的产前起源较少见,要么与ALL病例相比,AML出生时白血病前期细胞负荷显著更低。